FLSM
AGIO icon

Frazier Life Sciences Management’s Agios Pharmaceuticals AGIO Stock Holding History

Frazier Life Sciences Management’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,256,080
Closed -$42.5M – 42
2026
Q1 		$42.5M Sell
1,256,080
-23,674
-2% -$671K 1.09% 20
2025
Q4 		$34.8M Hold
1,279,754
– – 0.94% 22
2025
Q3 		$51.4M Hold
1,279,754
– – 1.54% 15
2025
Q2 		$42.6M Buy
1,279,754
+209,900
+20% +$6.36M 1.7% 15
2025
Q1 		$31.3M Buy
1,069,854
+100
+0% +$3.32K 1.43% 18
2024
Q4 		$35.2M Buy
1,069,754
+25,600
+2% +$1.2M 1.46% 17
2024
Q3 		$46.4M Buy
1,044,154
+172,180
+20% +$7.82M 1.86% 16
2024
Q2 		$37.6M Buy
871,974
+348,808
+67% +$12.6M 1.76% 18
2024
Q1 		$15.3M Hold
523,166
– – 0.65% 34
2023
Q4 		$11.7M Buy
523,166
+231,164
+79% +$5.18M 0.62% 40
2023
Q3 		$7.23M Buy
+292,002
New +$7.72M 0.48% 37

Other funds holding AGIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Frazier Life Sciences Management's AGIO Position: Q2 2026 in Review

Frazier Life Sciences Management sold out of Agios Pharmaceuticals (AGIO) in Q2 2026, closing a stake of 1,256,080 shares — an estimated $42.5M sold.

Frazier Life Sciences Management first reported a position in AGIO in Q3 2023 and held it in 11 quarters. The position peaked at $51.4M in Q3 2025. 238 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

  • Frazier Life Sciences Management reported no remaining Agios Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Frazier Life Sciences Management sold 1,256,080 Agios Pharmaceuticals shares in Q2 2026, an estimated $42.5M.
  • Frazier Life Sciences Management first reported a position in Agios Pharmaceuticals in Q3 2023 and held it in 11 quarters.
  • Frazier Life Sciences Management's Agios Pharmaceuticals position peaked at $51.4M in Q3 2025.
  • 238 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on Frazier Life Sciences Management's 13F filing for Q2 2026, filed 14 Aug 2026.